Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (21)	11/5/1999 2:59:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 81

A little leaner: Valentis, Inc. Announces Business Reorganization biz.yahoo.com Yahoo thread is a little nervous about departures, to me it just looks like they're getting a little more focused...Benjamin F. McGraw, President and Chief Executive Officer of Valentis noted, ''We believe that mergers are the most expeditious route to the creation of additional products for clinical development, and this has turned out to be true. We now have multiple clinical candidates and are restructuring the company to most efficiently develop these as products.'' CCM55 on Yahoo noted in message 212: Rodney Pearlman is well known and widely respected. What Valentis hasn't announced is that John Warner (Vice President,Research & Development) has also left. Only Alain Rolland is left as VP of Research. The stock was down a quarter an hour before the close at 3 3/4 on a lackluster day for microcap/smallcap biotech, and the major indexes up over a percent.